Cardiomyopathies and a brief insight into DOX-induced cardiomyopathy DOI Creative Commons

Sampat Singh Tanwar,

Sumeet Dwivedi,

Sheema Khan

et al.

The Egyptian Heart Journal, Journal Year: 2025, Volume and Issue: 77(1)

Published: March 10, 2025

Abstract Background Cardiomyopathy is a heterogeneous group of myocardial disorders characterized by structural and functional abnormalities the heart muscle. It classified into primary (genetic, mixed, or acquired) secondary categories, resulting in various phenotypes including dilated, hypertrophic, restrictive patterns. Hypertrophic cardiomyopathy, most common form, can cause exertional dyspnea, presyncope, sudden cardiac death. Dilated cardiomyopathy typically presents with failure symptoms, while rarer often associated systemic diseases. Diagnosis involves comprehensive evaluation history, physical examination, electrocardiography, echocardiography. Treatment options range from pharmacotherapy lifestyle modifications to implantable cardioverter-defibrillators transplantation refractory cases. Main body Anthracyclines, particularly doxorubicin, have emerged as crucial components cancer treatment, demonstrating significant antitumor activity across malignancies. These drugs become standard numerous chemotherapy regimens, improving patient outcomes. However, their use severe cardiotoxicity, failure. The mechanisms anthracycline action toxicity are complex, involving DNA damage, iron-mediated free radical production, disruption cardiovascular homeostasis. Doxorubicin-induced (DIC) complication treatment poor prognosis limited effective treatments. pathophysiology DIC multiple mechanisms, oxidative stress, inflammation, mitochondrial calcium homeostasis disorder. Despite extensive research, no for established currently available. Dexrazoxane only FDA-approved protective agent, but it has limitations. Recent studies explored potential therapeutic approaches, natural drugs, endogenous substances, new dosage forms, herbal medicines. lack experimental models incorporating pre-existing limits understanding efficacy. Conclusion Cardiomyopathy, whether secondary, poses clinical challenge due its varying etiologies advanced stages. Anthracycline-induced chemotherapy, doxorubicin being notable contributor. advancements therapies, cardiotoxic effects anthracyclines necessitate further investigation preventive strategies interventions improve

Language: Английский

Cardiomyopathies and a brief insight into DOX-induced cardiomyopathy DOI Creative Commons

Sampat Singh Tanwar,

Sumeet Dwivedi,

Sheema Khan

et al.

The Egyptian Heart Journal, Journal Year: 2025, Volume and Issue: 77(1)

Published: March 10, 2025

Abstract Background Cardiomyopathy is a heterogeneous group of myocardial disorders characterized by structural and functional abnormalities the heart muscle. It classified into primary (genetic, mixed, or acquired) secondary categories, resulting in various phenotypes including dilated, hypertrophic, restrictive patterns. Hypertrophic cardiomyopathy, most common form, can cause exertional dyspnea, presyncope, sudden cardiac death. Dilated cardiomyopathy typically presents with failure symptoms, while rarer often associated systemic diseases. Diagnosis involves comprehensive evaluation history, physical examination, electrocardiography, echocardiography. Treatment options range from pharmacotherapy lifestyle modifications to implantable cardioverter-defibrillators transplantation refractory cases. Main body Anthracyclines, particularly doxorubicin, have emerged as crucial components cancer treatment, demonstrating significant antitumor activity across malignancies. These drugs become standard numerous chemotherapy regimens, improving patient outcomes. However, their use severe cardiotoxicity, failure. The mechanisms anthracycline action toxicity are complex, involving DNA damage, iron-mediated free radical production, disruption cardiovascular homeostasis. Doxorubicin-induced (DIC) complication treatment poor prognosis limited effective treatments. pathophysiology DIC multiple mechanisms, oxidative stress, inflammation, mitochondrial calcium homeostasis disorder. Despite extensive research, no for established currently available. Dexrazoxane only FDA-approved protective agent, but it has limitations. Recent studies explored potential therapeutic approaches, natural drugs, endogenous substances, new dosage forms, herbal medicines. lack experimental models incorporating pre-existing limits understanding efficacy. Conclusion Cardiomyopathy, whether secondary, poses clinical challenge due its varying etiologies advanced stages. Anthracycline-induced chemotherapy, doxorubicin being notable contributor. advancements therapies, cardiotoxic effects anthracyclines necessitate further investigation preventive strategies interventions improve

Language: Английский

Citations

0